May 13, 2026
Chondroitin Sulfate Sourcing in 2026: What 240 Million Osteoarthritis Patients Mean For Supply
Osteoarthritis affects over 240 million people worldwide. And the number of people over 60 is set to double by 2050. Here's what that means for the chondroit...
-
![Global First, China Debut: Yanhong Pharmaceutical's Non-Invasive Treatment Fo...]()
Mar 06, 2026Global First, China Debut: Yanhong Pharmaceutical's Non-Invasive Treatment Fo...(China, March 3, 2026) Yanhong Pharmaceutical (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on urogenital tumors and ...view more -
![Blockbuster Grand Slam! Roche’s Oral BTK Inhibitor Secures Third Phase III Tr...]()
Mar 05, 2026Blockbuster Grand Slam! Roche’s Oral BTK Inhibitor Secures Third Phase III Tr...On March 2, Roche officially announced that its investigational Bruton's tyrosine kinase (BTK) inhibitor, fenebrutinib, successfully met the primar...view more -
![New Advances in Anti-Aging Drugs]()
Feb 27, 2026New Advances in Anti-Aging DrugsIn recent years, with key breakthroughs in fundamental research such as cellular aging mechanisms and gene regulation in life sciences, a series of...view more -
![2026 JPM: Chinese Innovative Drugs, From Being Scrutinized To Being Embraced]()
Feb 12, 20262026 JPM: Chinese Innovative Drugs, From Being Scrutinized To Being EmbracedThe 2026 JPM Healthcare Conference felt much like the ones before: the crowds were back, and hotel prices in downtown San Francisco's Union Square...view more -
![2026 JPM: The Preemptive Battle For The Next Blockbuster King]()
Feb 11, 20262026 JPM: The Preemptive Battle For The Next Blockbuster King Data shows that pharmaceutical giants face patent expirations for over $100 billion worth of drugs by 2030. For example, Merck's PD-1 inhibitor K...view more -
![Which “No Cure in Sight” Diseases May Be Ended in 2026?]()
Feb 10, 2026Which “No Cure in Sight” Diseases May Be Ended in 2026? In the 2026 FDA new drug review cycle, some candidate drugs target treatment gaps-conditions for which there are no approved specialized therapie...view more -
![The Anti-aging Sector Welcomes A New Game-changer]()
Jan 29, 2026The Anti-aging Sector Welcomes A New Game-changerOn January 25, 2026, Kangnuo Biotech submitted an application for a main board listing on the Hong Kong Stock Exchange. Driven by "AI + synthe...view more -
![Panorama Of Flavonoid Drug Development: 19 Marketed, 20 in Clinical Trials]()
Jan 28, 2026Panorama Of Flavonoid Drug Development: 19 Marketed, 20 in Clinical TrialsHangzhou Jeci Biochemical Technology Co., Ltd. is a physical and chemical enterprise mainly based on pharmaceutical and chemical industry. The comp...view more -
![Autoimmune ADCs Are On The Verge Of Explosive Growth]()
Jan 27, 2026Autoimmune ADCs Are On The Verge Of Explosive GrowthHangzhou Jeci Biochemical Technology Co., Ltd. is a physical and chemical enterprise mainly based on pharmaceutical and chemical industry. The comp...view more -
![Top 5 Ogliegron Manufacturers in China]()
Jan 27, 2026Top 5 Ogliegron Manufacturers in ChinaHangzhou Jeci Biochemical Technology Co., Ltd. is a physical and chemical enterprise mainly based on pharmaceutical and chemical industry. The comp...view more -
![Top 10 Factories Of Deflazacort Intermediates in China]()
Dec 29, 2025Top 10 Factories Of Deflazacort Intermediates in ChinaHangzhou Jeci Biochemical Technology Co., Ltd. is a physical and chemical enterprise mainly based on pharmaceutical and chemical industry. The comp...view more -
![Hangzhou Jeci Biochem Technology Co., Ltd. Can Supply Advanced Intermediates ...]()
Dec 11, 2025Hangzhou Jeci Biochem Technology Co., Ltd. Can Supply Advanced Intermediates ...Hangzhou Jeci Biochem Technology Co., Ltd. can supply advanced intermediates of Iptacopan (CAS: 1644667‑61‑7, CAS: 1481631‑51‑9, CAS: 2803364‑77‑2,...view more
